Pliant Therapeutics, Inc. (FRA:9PT)

Market Cap	66.60M -4.9%
Revenue (ttm)	n/a
Net Income	-127.20M
EPS	-2.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	1.107
Previous Close	1.115
Day's Range	1.107 - 1.107
52-Week Range	0.870 - 1.200
Beta	n/a
RSI	48.18
Earnings Date	May 6, 2026

About Pliant Therapeutics

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of αvß8 and αvß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics,...

• Industry: Pharmaceutical Preparations
• Founded: 2015
• Employees: 49
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9PT

Financial Performance

Financial numbers in USD